000157718 001__ 157718
000157718 005__ 20240328115555.0
000157718 0247_ $$2doi$$a10.3389/fneur.2021.644064
000157718 0247_ $$2pmid$$apmid:34113306
000157718 0247_ $$2pmc$$apmc:PMC8186498
000157718 0247_ $$2altmetric$$aaltmetric:106400229
000157718 037__ $$aDZNE-2021-01175
000157718 041__ $$aEnglish
000157718 082__ $$a610
000157718 1001_ $$0P:(DE-2719)2811600$$aRespondek, Gesine$$b0$$udzne
000157718 245__ $$aDescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy.
000157718 260__ $$aLausanne$$bFrontiers Research Foundation$$c2021
000157718 3367_ $$2DRIVER$$aarticle
000157718 3367_ $$2DataCite$$aOutput Types/Journal article
000157718 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711546189_24241
000157718 3367_ $$2BibTeX$$aARTICLE
000157718 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157718 3367_ $$00$$2EndNote$$aJournal Article
000157718 520__ $$aBackground: The German research networks DescribePSP and ProPSP prospectively collect comprehensive clinical data, imaging data and biomaterials of patients with a clinical diagnosis of progressive supranuclear palsy. Progressive supranuclear palsy is a rare, adult-onset, neurodegenerative disease with striking clinical heterogeneity. Since now, prospective natural history data are largely lacking. Clinical research into treatment strategies has been limited due to delay in clinical diagnosis and lack of natural history data on distinct clinical phenotypes. Methods: The DescribePSP network is organized by the German Center for Neurodegenerative Diseases. DescribePSP is embedded in a larger network with parallel cohorts of other neurodegenerative diseases and healthy controls. The DescribePSP network is directly linked to other Describe cohorts with other primary diagnoses of the neurodegenerative and vascular disease spectrums and also to an autopsy program for clinico-pathological correlation. The ProPSP network is organized by the German Parkinson and Movement Disorders Society. Both networks follow the same core protocol for patient recruitment and collection of data, imaging and biomaterials. Both networks host a web-based data registry and a central biorepository. Inclusion/exclusion criteria follow the 2017 Movement Disorder Society criteria for the clinical diagnosis of progressive supranuclear palsy. Results: Both networks started recruitment of patients by the end of 2015. As of November 2020, N = 354 and 269 patients were recruited into the DescribePSP and the ProPSP studies, respectively, and N = 131 and 87 patients received at least one follow-up visit. Conclusions: The DescribePSP and ProPSP networks are ideal resources for comprehensive natural history data of PSP, including imaging data and biological samples. In contrast to previous natural history studies, DescribePSP and ProPSP include not only patients with Richardson's syndrome, but also variant PSP phenotypes as well as patients at very early disease stages, before a diagnosis of possible or probable PSP can be made. This will allow for identification and evaluation of early biomarkers for diagnosis, prognosis, and progression.
000157718 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000157718 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000157718 650_7 $$2Other$$abiobank
000157718 650_7 $$2Other$$acorticobasal syndrome
000157718 650_7 $$2Other$$adisease networks
000157718 650_7 $$2Other$$anatural history
000157718 650_7 $$2Other$$aprogressive supranuclear palsy
000157718 650_7 $$2Other$$arare neurological disease
000157718 693__ $$0EXP:(DE-2719)DESCRIBE-PSP-20160101$$5EXP:(DE-2719)DESCRIBE-PSP-20160101$$eDZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)$$x0
000157718 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b1$$eLast author$$udzne
000157718 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2021.644064$$gVol. 12, p. 644064$$p644064$$tFrontiers in neurology$$v12$$x1664-2295$$y2021
000157718 8564_ $$uhttps://pub.dzne.de/record/157718/files/DZNE-2021-01175.pdf$$yOpenAccess
000157718 8564_ $$uhttps://pub.dzne.de/record/157718/files/DZNE-2021-01175.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000157718 909CO $$ooai:pub.dzne.de:157718$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000157718 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811600$$aExternal Institute$$b0$$kExtern
000157718 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000157718 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000157718 9141_ $$y2021
000157718 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000157718 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000157718 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000157718 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2021$$d2022-11-18
000157718 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000157718 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000157718 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000157718 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000157718 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000157718 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000157718 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000157718 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:11:28Z
000157718 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000157718 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000157718 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000157718 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000157718 980__ $$ajournal
000157718 980__ $$aVDB
000157718 980__ $$aUNRESTRICTED
000157718 980__ $$aI:(DE-2719)1111015
000157718 9801_ $$aFullTexts